ClinicalTrials.gg
CompletedNCT03956355Updated Jun 12, 2025Results posted

Tapinarof for the Treatment of Plaque Psoriasis in Adults (3001)

A Phase 3 interventional study of Tapinarof and Vehicle Cream in Plaque Psoriasis, sponsored by Organon and Co. Completed at 53 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-06-12.

Sponsored by Organon and Co · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
510
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing tapinarof in Psoriasis — 3 open to participants now, 3 under way, 1 of them phase 3. tapinarof · Psoriasis.

Enrollment
5th of 19
510 · median 58
Started
2019
with 3 others
Phase 3
5 of 19
none open now
Registered
6th of 19
by date
Lead sponsor
7 of 19
Organon and Co

Among the 19 studies testing tapinarof in Psoriasis, this one is the 5th largest by enrollment, is one of 4 that started in 2019, is one of 5 in phase 3, and was the 6th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

3 of the 19 studies testing tapinarof in Psoriasis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About tapinarof

tapinarof: first FDA approval 2022 (VTAMA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing tapinarof in Psoriasis, or all of them as a file.
02

Study summary

This is a randomized, double-blind, vehicle-controlled Phase 3 study to evaluate the efficacy and safety of topical tapinarof cream, 1% once daily for the treatment of plaque psoriasis in adults. Approximately 500 adult subjects with plaque psoriasis will be randomized 2:1 to receive either tapinarof cream, 1% or matching vehicle cream once daily for 12 weeks.

Read the detailed description

This study is a 12-week double-blind, vehicle-controlled treatment study in which subjects will be randomized to receive tapinarof cream, 1% or vehicle cream once daily for 12 weeks. At the end of the 12-week study treatment, qualified subjects completing the study will have the option to enter a separate open-label, long-term safety and efficacy study for an additional 40 weeks of treatment with tapinarof cream, 1%. Subjects who do not enroll in the open-label long-term study will complete a follow-up visit approximately 4 weeks after end of treatment in this study (at Week 16).

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

Keywords

  • Tapinarof
  • plaque psoriasis
  • adult
  • phase 3
  • topical
  • double-blind
  • efficacy
  • safety
  • psoriasis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects ages 18 to 75 years with clinical diagnosis of chronic plaque psoriasis and stable disease for at least 6 months prior to the study.
  • BSA involvement ≥ 3% and ≤ 20%
  • A PGA score of 2 (mild), 3 (moderate) or 4 (severe) at screening and baseline
  • Females of child bearing potential and male subjects who are engaging in sexual activity that could lead to pregnancy agree to follow the specified guidance throughout the study, including screening, during the treatment period, and for at least 4 weeks after the last exposure to study treatment
  • Capable of giving written

Exclusion criteria

Exclusion Criteria:

  • Psoriasis other than plaque variant
  • Any sign of infection of any of the psoriatic lesions
  • Concurrent conditions or history of other diseases:
  • at Screening
  • Chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 4 weeks prior to the Baseline visit
  • Acute active bacterial, fungal, or viral (herpes simplex, herpes zoster, chicken pox) skin infection within 1 week prior to the Baseline visit
  • Significant dermatologic or inflammatory condition other than plaque psoriasis that, in the Investigator's opinion, would make it difficult to interpret data or assessments during the study
  • (ALT) or aspartate aminotransferase (AST) ≥ 1.5x the (ULN)
  • Total > 1.5 x ULN; total bilirubin > ULN and ≤ 1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin \< 35%
  • interval > 475
  • Current or chronic history of liver disease, known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones), presence of surface antigen (HBsAg), or positive antibody test result, or a positive anti-hepatitis B core antigen (anti-HBc) result
  • Ultraviolet (UV) light therapy or prolonged exposure to natural or artificial sources of UV radiation within 4 weeks prior to the Baseline visit and/or plans to have such exposures during the study which could potentially impact the subject's psoriasis
  • Use of any prohibited medication within the indicated period before the first dose of study drug
  • Within a minimum of 5 half-lives for biologic agents:
  • Within 4 weeks for systemic immunosuppressive or immunomodulating agents, fumaric acid derivatives, vitamin D3 and analogs, retinoids, psoralens, , adrenocorticotropic hormone analogs, and tazarotene
  • 2 weeks for immunizations with a live viral component; drugs known to possibly worsen psoriasis, unless on a stable dose for > 12 weeks
  • With the exception of non-medicated emollients, 2 weeks for topical treatments including corticosteroids, immunomodulators, anthralin (dithranol), vitamin D derivatives or coal tar.
  • Pregnant females or lactating females
  • History of sensitivity to the study drugs, or components thereof or a history of drug or other allergy that, in the opinion of the Investigator or Medical Monitor, contraindicates the subject's participation in the study
  • The subject has received an product within 30 days, 5 half-lives, or twice the duration of the biological effect of the study drug (whichever is longer) prior to first dose of study drug
  • Current or a history of cancer within 5 years except for fully excised skin basal cell carcinoma, squamous cell carcinoma or carcinoma in situ of the cervix
  • Subjects with active infection that required oral, intramuscular, or intravenous administration of antibiotics, antifungal or antiviral agents within 7 days of Baseline/Day 1
  • Previous known participation in a clinical study with tapinarof
  • Evidence of significant hepatic, renal, respiratory, endocrine, hematologic, neurologic, psychiatric, or cardiovascular (CV) system abnormalities or laboratory abnormality that will affect the health of the subject or interfere with interpretation of the results
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
510 participants (actual)

Study arms

  • Experimental
    Tapinarof (DMVT-505)

    Tapinarof (DMVT-505) Cream Group

    Drug: Tapinarof

  • Placebo comparator
    Vehicle Cream

    Vehicle Cream Group

    Drug: Vehicle Cream

Interventions

  • Tapinarof cream, 1%, applied once daily

    Also known as: DMVT-505

  • DrugVehicle Cream

    Vehicle cream applied once daily

06

What researchers measure

Primary outcomes

  1. Percent of Subjects Who Achieve a Physician Global Assessment (PGA) Score of Clear (0) or Almost Clear (1) With a Minimum 2-grade Improvement From Baseline at Week 12. Analyses Were Done Using Multiple Imputation

    The PGA is a clinical tool for assessing the current state/severity of a subject's psoriasis at a given timepoint. A static 5-point scale is used to grade lesions on the clinical characteristics of erythema, scaling, and plaque thickness/elevation. The PGA ranges from 0 to 4, and is calculated as Clear (0), Almost clear (1), Mild (2), Moderate (3), and Severe (4). Higher PGA scores represent more severe disease. Analyses were done using multiple imputation.

    Time frame: Baseline to Week 12

Secondary outcomes

  1. Percent of Subjects With ≥ 75% Improvement in Psoriasis Area and Severity Index (PASI) From Baseline at Week 12. Analyses Were Done Using Multiple Imputation.

    The Psoriasis Area and Severity Index (PASI) scoring system combines the assessment of lesion severity and extent of affected area into a single score: 0 (no disease) to 72 (maximal disease). The body is divided into 4 areas for scoring (head, arms, trunk, and legs). Each area is assessed for 3 signs: erythema (redness), induration (plaque thickness), and scale. The severity of each sign in each body area is assessed and scored independently using a 5-point scale, where 0=none, 1=slight, 2=mild, 3=moderate, 4=severe. Each area is also assessed for percent of skin involved: 0 = (0%), 1 = (1-\<10%), 2 = (10-\<30%), 3 = (30-\<50%), 4 = (50 -\<70%), 5 = (70-\<90%), 6 = (90-100%). The individual scores are multiplied by a weighted factor for each body region; the sum of these scores gives the overall PASI score. Higher scores indicate more severe disease. PASI is a static assessment made without reference to previous scores. Analyses were done using multiple imputation.

    Time frame: Baseline to Week 12

  2. Percent of Subjects With a PGA Score of 0 or 1 at Week 12. Analyses Were Done Using Multiple Imputation.

    The PGA is a clinical tool for assessing the current state/severity of a subject's psoriasis at a given timepoint. A static 5-point scale is used to grade lesions on the clinical characteristics of erythema, scaling, and plaque thickness/elevation. The PGA ranges from 0 to 4, and is calculated as Clear (0), Almost clear (1), Mild (2), Moderate (3), and Severe (4). Higher PGA scores represent more severe disease. Analyses were done using multiple imputation.

    Time frame: Baseline to Week 12

  3. Mean Change in Percent of Total Body Surface Area (%BSA) Affected From Baseline to Week 12

    Assessment of BSA with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. Body regions are assigned specific number of handprints with percentage \[Head and neck = 10% (10 handprints), upper extremities = 20% (20 handprints), Trunk (including axillae and groin) = 30% (30 handprints), lower extremities (including buttocks) = 40% (40 handprints)\]. Estimates of the % involvement in each body region will be multiplied by the fraction of total body area to obtain the total %BSA involved by region and overall.

    Time frame: Baseline to Week 12

  4. Percent of Subjects With ≥90% Improvement in PASI Score From Baseline to Week 12. Analyses Were Done Using Multiple Imputation.

    The Psoriasis Area and Severity Index (PASI) scoring system combines the assessment of lesion severity and extent of affected area into a single score: 0 (no disease) to 72 (maximal disease). The body is divided into 4 areas for scoring (head, arms, trunk, and legs). Each area is assessed for 3 signs: erythema (redness), induration (plaque thickness), and scale. The severity of each sign in each body area is assessed and scored independently using a 5-point scale, where 0=none, 1=slight, 2=mild, 3=moderate, 4=severe. Each area is also assessed for percent of skin involved: 0 = (0%), 1 = (1-\<10%), 2 = (10-\<30%), 3 = (30-\<50%), 4 = (50 -\<70%), 5 = (70-\<90%), 6 = (90-100%). The individual scores are multiplied by a weighted factor for each body region; the sum of these scores gives the overall PASI score. Higher scores indicate more severe disease. PASI is a static assessment made without reference to previous scores. Analyses were done using multiple imputation.

    Time frame: Baseline to Week 12

07

Results

Posted Oct 13, 2022

Participant flow

Participant flow — Overall Study
MilestoneTapinarof (DMVT-505)Vehicle Cream
Started340170
Completed269130
Not completed7140

Outcome measures

PrimaryPercent of Subjects Who Achieve a Physician Global Assessment (PGA) Score of Clear (0) or Almost Clear (1) With a Minimum 2-grade Improvement From Baseline at Week 12. Analyses Were Done Using Multiple Imputation

The PGA is a clinical tool for assessing the current state/severity of a subject's psoriasis at a given timepoint. A static 5-point scale is used to grade lesions on the clinical characteristics of erythema, scaling, and plaque thickness/elevation. The PGA ranges from 0 to 4, and is calculated as Clear (0), Almost clear (1), Mild (2), Moderate (3), and Severe (4). Higher PGA scores represent more severe disease. Analyses were done using multiple imputation.

Time frame:
Baseline to Week 12
Reported as:
Mean · percentage of subjects
Percent of Subjects Who Achieve a Physician Global Assessment (PGA) Score of Clear (0) or Almost Clear (1) With a Minimum 2-grade Improvement From Baseline at Week 12. Analyses Were Done Using Multiple Imputation
percentage of subjectsTapinarof (DMVT-505)Vehicle Cream
Percent of Subjects Who Achieve a Physician Global Assessment (PGA) Score of Clear (0) or Almost Clear (1) With a Minimum 2-grade Improvement From Baseline at Week 12. Analyses Were Done Using Multiple Imputation35.4 ± 2.756.0 ± 2.08
Statistical analysis
  • Tapinarof (DMVT-505) vs Vehicle Cream · Cochran-Mantel-Haenszel · p = <0.0001 · Risk ratio (rr): 5.78
SecondaryPercent of Subjects With ≥ 75% Improvement in Psoriasis Area and Severity Index (PASI) From Baseline at Week 12. Analyses Were Done Using Multiple Imputation.

The Psoriasis Area and Severity Index (PASI) scoring system combines the assessment of lesion severity and extent of affected area into a single score: 0 (no disease) to 72 (maximal disease). The body is divided into 4 areas for scoring (head, arms, trunk, and legs). Each area is assessed for 3 signs: erythema (redness), induration (plaque thickness), and scale. The severity of each sign in each body area is assessed and scored independently using a 5-point scale, where 0=none, 1=slight, 2=mild, 3=moderate, 4=severe. Each area is also assessed for percent of skin involved: 0 = (0%), 1 = (1-\<10%), 2 = (10-\<30%), 3 = (30-\<50%), 4 = (50 -\<70%), 5 = (70-\<90%), 6 = (90-100%). The individual scores are multiplied by a weighted factor for each body region; the sum of these scores gives the overall PASI score. Higher scores indicate more severe disease. PASI is a static assessment made without reference to previous scores. Analyses were done using multiple imputation.

Time frame:
Baseline to Week 12
Reported as:
Mean · percentage of subjects
Percent of Subjects With ≥ 75% Improvement in Psoriasis Area and Severity Index (PASI) From Baseline at Week 12. Analyses Were Done Using Multiple Imputation.
percentage of subjectsTapinarof (DMVT-505)Vehicle Cream
Percent of Subjects With ≥ 75% Improvement in Psoriasis Area and Severity Index (PASI) From Baseline at Week 12. Analyses Were Done Using Multiple Imputation.36.1 ± 2.7310.2 ± 2.43
Statistical analysis
  • Tapinarof (DMVT-505) vs Vehicle Cream · Cochran-Mantel-Haenszel · p = <0.0001 · Risk ratio (rr): 2.76
SecondaryPercent of Subjects With a PGA Score of 0 or 1 at Week 12. Analyses Were Done Using Multiple Imputation.

The PGA is a clinical tool for assessing the current state/severity of a subject's psoriasis at a given timepoint. A static 5-point scale is used to grade lesions on the clinical characteristics of erythema, scaling, and plaque thickness/elevation. The PGA ranges from 0 to 4, and is calculated as Clear (0), Almost clear (1), Mild (2), Moderate (3), and Severe (4). Higher PGA scores represent more severe disease. Analyses were done using multiple imputation.

Time frame:
Baseline to Week 12
Reported as:
Mean · percentage of subjects
Percent of Subjects With a PGA Score of 0 or 1 at Week 12. Analyses Were Done Using Multiple Imputation.
percentage of subjectsTapinarof (DMVT-505)Vehicle Cream
Percent of Subjects With a PGA Score of 0 or 1 at Week 12. Analyses Were Done Using Multiple Imputation.37.8 ± 2.799.9 ± 2.51
Statistical analysis
  • Tapinarof (DMVT-505) vs Vehicle Cream · Cochran-Mantel-Haenszel · p = 0.0001 · Risk ratio (rr): 2.68
SecondaryMean Change in Percent of Total Body Surface Area (%BSA) Affected From Baseline to Week 12

Assessment of BSA with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. Body regions are assigned specific number of handprints with percentage \[Head and neck = 10% (10 handprints), upper extremities = 20% (20 handprints), Trunk (including axillae and groin) = 30% (30 handprints), lower extremities (including buttocks) = 40% (40 handprints)\]. Estimates of the % involvement in each body region will be multiplied by the fraction of total body area to obtain the total %BSA involved by region and overall.

Time frame:
Baseline to Week 12
Reported as:
Least squares mean · Mean change from Baseline
Mean Change in Percent of Total Body Surface Area (%BSA) Affected From Baseline to Week 12
Mean change from BaselineTapinarof (DMVT-505)Vehicle Cream
Mean Change in Percent of Total Body Surface Area (%BSA) Affected From Baseline to Week 12-3.50 ± 0.471-0.22 ± 0.579
Statistical analysis
  • Tapinarof (DMVT-505) vs Vehicle Cream · ANCOVA · p = <0.0001 · Least squares mean difference: -3.28
SecondaryPercent of Subjects With ≥90% Improvement in PASI Score From Baseline to Week 12. Analyses Were Done Using Multiple Imputation.

The Psoriasis Area and Severity Index (PASI) scoring system combines the assessment of lesion severity and extent of affected area into a single score: 0 (no disease) to 72 (maximal disease). The body is divided into 4 areas for scoring (head, arms, trunk, and legs). Each area is assessed for 3 signs: erythema (redness), induration (plaque thickness), and scale. The severity of each sign in each body area is assessed and scored independently using a 5-point scale, where 0=none, 1=slight, 2=mild, 3=moderate, 4=severe. Each area is also assessed for percent of skin involved: 0 = (0%), 1 = (1-\<10%), 2 = (10-\<30%), 3 = (30-\<50%), 4 = (50 -\<70%), 5 = (70-\<90%), 6 = (90-100%). The individual scores are multiplied by a weighted factor for each body region; the sum of these scores gives the overall PASI score. Higher scores indicate more severe disease. PASI is a static assessment made without reference to previous scores. Analyses were done using multiple imputation.

Time frame:
Baseline to Week 12
Reported as:
Mean · percentage of subjects
Percent of Subjects With ≥90% Improvement in PASI Score From Baseline to Week 12. Analyses Were Done Using Multiple Imputation.
percentage of subjectsTapinarof (DMVT-505)Vehicle Cream
Percent of Subjects With ≥90% Improvement in PASI Score From Baseline to Week 12. Analyses Were Done Using Multiple Imputation.18.8 ± 2.181.6 ± 1.05
Statistical analysis
  • Tapinarof (DMVT-505) vs Vehicle Cream · Cochran-Mantel-Haenszel · p = 0.0005 · Risk ratio (rr): 8.54

Adverse events

Collected over Subject duration: 12 weeks of treatment and 4 week follow-up for subjects not enrolled in the long-term extension study (DMVT-505-3003). Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tapinarof (DMVT-505)0/340 (0%)9/340 (2.6%)131/340 (38.5%)
Vehicle Cream0/170 (0%)0/170 (0%)27/170 (15.9%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventTapinarof (DMVT-505)Vehicle Cream
Cardiac failure congestiveCardiac disorders1/3400/170
Coronary artery diseaseCardiac disorders1/3400/170
Pericardial effusionCardiac disorders1/3400/170
Oesophageal obstructionGastrointestinal disorders1/3400/170
Pancreatitis acuteGastrointestinal disorders1/3400/170
CellulitisInfections and infestations1/3400/170
Stab woundInjury, poisoning and procedural complications1/3400/170
LaryngospasmRespiratory, thoracic and mediastinal disorders1/3400/170
Aortic arteriosclerosisVascular disorders1/3400/170
Hypertensive crisisVascular disorders1/3400/170
Most frequent other events
Showing 10 of 15
Most frequent other events
EventTapinarof (DMVT-505)Vehicle Cream
FolliculitisInfections and infestations79/3402/170
NasopharyngitisInfections and infestations25/34010/170
Dermatitis contactSkin and subcutaneous tissue disorders15/3401/170
HeadacheNervous system disorders10/3403/170
Upper respiratory tract infectionInfections and infestations5/3404/170
PruritusSkin and subcutaneous tissue disorders8/3400/170
Viral upper respiratory tract infectionInfections and infestations7/3402/170
InfluenzaInfections and infestations5/3400/170
abdominal painGastrointestinal disorders4/3400/170
CystitisInfections and infestations0/3402/170

Baseline characteristics

Age, Continuous
Age, Continuous(years)Tapinarof (DMVT-505)Vehicle CreamTotal
Mean49.8 ± 13.6849.1 ± 13.2549.6 ± 13.53
Sex: Female, Male
Sex: Female, Male(Participants)Tapinarof (DMVT-505)Vehicle CreamTotal
Female12784211
Male21386299
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Tapinarof (DMVT-505)Vehicle CreamTotal
Hispanic or Latino533487
Not Hispanic or Latino284135419
Unknown or Not Reported314
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Tapinarof (DMVT-505)Vehicle CreamTotal
American Indian or Alaska Native000
Asian21425
Native Hawaiian or Other Pacific Islander101
Black or African American181129
White286146432
More than one race10717
Unknown or Not Reported426
Physician Global Assessment
Physician Global Assessment(Participants)Tapinarof (DMVT-505)Vehicle CreamTotal
0 - clear000
1 - almost clear000
2 - mild392160
3 - moderate271133404
4 - severe301646
Psoriasis Area and Severity Index
Psoriasis Area and Severity Index(units on a scale)Tapinarof (DMVT-505)Vehicle CreamTotal
Mean8.71 ± 3.9799.19 ± 4.3958.87 ± 4.124
Percent Body Surface Area
Percent Body Surface Area(Percent)Tapinarof (DMVT-505)Vehicle CreamTotal
Mean7.8 ± 4.648.2 ± 5.067.9 ± 4.78
08

Study locations

53 sites
  • Dermavant Investigative Site
    Birmingham, Alabama 35205, United States
  • Dermavant Investigative Site
    Phoenix, Arizona 85032, United States
  • Dermavant Investigative Site
    Hot Springs, Arkansas 71913, United States
  • Dermavant Investigative Site
    Rogers, Arkansas 72758, United States
  • Dermavant Investigative Site
    Anaheim Hills, California 92807, United States
  • Dermavant Investigative Site
    Fresno, California 93720, United States
  • Dermavant Investigative Site
    Los Angeles, California 90033, United States
  • Dermavant Investigative Site
    Northridge, California 91324, United States
  • Dermavant Investigative Site
    San Diego, California 92123, United States
  • Dermavant Investigative Site
    Santa Ana, California 92701, United States
  • Dermavant Investigative Site
    Cromwell, Connecticut 06416, United States
  • Dermavant Investigative Site
    Boca Raton, Florida 33431, United States
  • Dermavant Investigative Site
    Brandon, Florida 33511, United States
  • Dermavant Investigative Site
    Hialeah, Florida 33016, United States
  • Dermavant Investigative Site
    Miramar, Florida 33027, United States
  • Dermavant Investigative Site
    Marietta, Georgia 30060, United States
  • Dermavant Investigative Site
    Evansville, Indiana 47714, United States
  • Dermavant Investigative Site
    Indianapolis, Indiana 46250, United States
  • Dermavant Investigative Site
    New Albany, Indiana 47150, United States
  • Dermavant Investigative Site
    Louisville, Kentucky 40202, United States
  • Dermavant Investigative Site
    Owensboro, Kentucky 42301, United States
  • Dermavant Investigative Site
    Baton Rouge, Louisiana 70809, United States
  • Dermavant Investigative Site
    New Orleans, Louisiana 70112, United States
  • Dermavant Investigative Site
    New Orleans, Louisiana 70115, United States
  • Dermavant Investigative Site
    Boston, Massachusetts 02115, United States
  • Dermavant Investigative Site
    Clarkston, Michigan 48346, United States
  • Dermavant Investigative Site
    Warren, Michigan 48088, United States
  • Dermavant Investigative Site
    Saint Joseph, Missouri 64506, United States
  • Dermavant Investigative Site
    Verona, New Jersey 07044, United States
  • Dermavant Investigative Site
    Kew Gardens, New York 11374, United States
  • Dermavant Investigative Site
    New York, New York 10029, United States
  • Dermavant Investigative Site
    Rochester, New York 14623, United States
  • Dermavant Investigative Site
    Cary, North Carolina 27518, United States
  • Dermavant Investigative Site
    High Point, North Carolina 27262, United States
  • Dermavant Investigative Site
    Norman, Oklahoma 73071, United States
  • Dermavant Investigative Site
    Portland, Oregon 97210, United States
  • Dermavant Investigative Site
    Pittsburgh, Pennsylvania 15213, United States
  • Dermavant Investigative Site
    Johnston, Rhode Island 02919, United States
  • Dermavant Investigative Site
    Arlington, Texas 76011, United States
  • Dermavant Investigative Site
    College Station, Texas 77802, United States
  • Dermavant Investigative Site
    Dripping Springs, Texas 78620, United States
  • Dermavant Investigative Site
    Houston, Texas 77004, United States
  • Dermavant Investigative Site
    San Antonio, Texas 78213, United States
  • Dermavant Investigative Site
    West Jordan, Utah 84088, United States
  • Dermavant Investigative Site
    Saint Johns, Newfoundland and Labrador A1C 2H5, Canada
  • Dermavant Investigative Site
    Ajax, Ontario L1S 7K8, Canada
  • Dermavant Investigative Site
    Coburg, Ontario K9A 0Z4, Canada
  • Dermavant Investigative Site
    North Bay, Ontario P1B 3Z7, Canada
  • Dermavant Investigative Site
    Richmond Hill, Ontario L4C 9M7, Canada
  • Dermavant Investigative Site
    Toronto, Ontario M3H 5Y8, Canada
  • Dermavant Investigative Site
    Waterloo, Ontario N2J 1C4, Canada
  • Dermavant Investigative Site
    Windsor, Ontario N8W 5L7, Canada
  • Dermavant Investigative Site
    Montréal, Quebec H2X 2V1, Canada
09

References and documents

Publications

  • Lebwohl MG, Stein Gold L, Strober B, Papp KA, Armstrong AW, Bagel J, Kircik L, Ehst B, Hong HC, Soung J, Fromowitz J, Guenthner S, Piscitelli SC, Rubenstein DS, Brown PM, Tallman AM, Bissonnette R. Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis. N Engl J Med. 2021 Dec 9;385(24):2219-2229. doi: 10.1056/NEJMoa2103629. PubMed 34879448 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2019 to primary completion in May 2020, 12 months.

Results were first posted in Oct 2022, 2 years 4 months after primary completion. A results delay was requested in Oct 2020.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 12 months is below that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2019
First posted
May 20, 2019
StartActual
May 21, 2019
Primary completionActual
May 26, 2020
CompletionActual
May 26, 2020
Results delay requested
Oct 7, 2020
Results first posted
Oct 13, 2022
Last update
Jun 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03956355
Lead sponsor
Organon and Co
Collaborators
IQVIA Biotech
Responsible party
Sponsor
First posted
May 20, 2019
Start date
May 21, 2019
Primary completion
May 26, 2020
Completion
May 26, 2020
Results posted
Oct 13, 2022
Last update
Jun 12, 2025

Study contacts

Victoria Butners
study director · Dermavant Sciences GmbH

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tapinarof

Start the discussion